About
Research
Patient Care
Education
Community
FY22 Prostate Cancer Research Program (PCRP)
The DoD Congressionally Directed Medical Research Programs: FY22 PCRP is currently accepting applications for multiple award mechanisms. Earliest LOI due: July 7, 2022.
FY22 Rare Cancers Research Program (RCRP)
The DoD Congressionally Directed Medical Research Programs: FY22 RCRP is currently accepting applications for multiple award mechanisms. Earliest preproposal/LOI due: June 22, 2022.
Advancing Health Equity QuickFire Challenge
Focus areas: Lung cancer, Multiple myeloma, Prostate cancer. Application due June 24, 2022.
Research Programs
Cancer research at UCI is organized into three specific programs that provide an interactive and collaborative infrastructure for cancer discovery, clinical investigation including early phase and investigator-initiated trials, and population-based cancer research.
Victoria’s Secret Global Fund for Women’s Cancers
Focus: Breast and gynecologic cancers; female investigators. $206K/2 years. Application due June 28, 2022.
Innovations for Vets: Lung Cancer & Physical Trauma
Focus: Lung cancer. Application due July 15, 2022.
FY22 Melanoma Research Program (MRP)
The DoD Congressionally Directed Medical Research Programs: FY22 MRP is currently accepting applications for multiple award mechanisms. LOI due Sept 14, 2022.
Elizabeth Brem, MD, on Frontline Management of CLL
In the last few years, frontline management of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has undergone a profound paradigm shift. First-line treatment with novel targeted therapies has become preferable to the use of chemoimmunotherapy regimens such as fludarabine, cyclophosphamide, and rituximab (FCR) -- the latter being largely reserved for patients younger than 65 with no comorbidities, and no 17p deletion or other TP53 mutations.
UC DDC Seed Grant RFA Cycle 2
The University of California Drug Discovery Consortium (UC DDC) aims to assist faculty researchers across the University of California advance the creation of drugs that address important unmet medical needs. In partnership with industrial sponsors, we provide seed funding that enables faculty members to advance promising drug discovery/development projects, with the goal of generating data that will enable them to secure federal, philanthropic, or commercial support and thus further advance their projects. $50K-100K/1 year. LOI due August 31, 2022.
Cancer Center Scientific Retreat
Annual Scientific Retreat open to Cancer Center members and UCI students to explore emerging themes in cancer research and foster collaborations.
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)
PAR-22-164. $500K/year (5 years). Multiple application deadlines. Earliest deadline for new applications: October 5, 2022. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
PAR-22-165. $275K/2 years. Multiple application deadlines. Earliest deadline for new applications: October 5, 2022. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.
Precision Approaches in Radiation Synthetic Combinations (PAIRS) (R01 Clinical Trial Optional)
PAR-22-198. Multiple application deadlines. LOI due 30 days before application due date. Earliest LOI due date (new): Sept 5, 2022. Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R01 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.
Precision Approaches in Radiation Synthetic Combinations (PAIRS) (R21 Clinical Trial Optional)
PAR-22-199. Multiple application deadlines. LOI due 30 days prior to application due date. Earliest LOI deadline (new): Sept 16, 2022 Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits R21 research projects that seek to investigate actionable synthetic vulnerabilities that can be conditionally paired with tumor responses to radiation therapy. The goal of the Precision Approaches in Radiation Synthetic Combinations (PAIRS) program is to develop radiation-synthetic combination strategies and facilitate their adoption into the precision medicine toolkit toward building new and effective anticancer treatments.
Clinical Research
At the UCI Chao Family Comprehensive Cancer Center — Orange County's only National Cancer Institute-designated comprehensive cancer center — patients receive compassionate and highly personalized treatment.
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
PAR-22-173. Multiple application deadlines. Earliest application due date: October 25, 2022.
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
PAR-22-174. Multiple application deadlines. Earliest application due date: October 25, 2022.
2022 Elsa U. Pardee Foundation Grant
Focus: Cancer detection, treatment, cures; New cancer researchers or new cancer approaches Requested budget must support scope of work - One year project period Three application cycles. Deadlines: December 15, April 30, August 31
Deaminet 2023
The primary goal of this conference is to bring together investigators interested in base editing enzymes, predominantly APOBEC and ADAR deaminase family members but also other promising enzymes, and discuss ways to harness their activities toward editing for beneficial purposes.
4th International Conference on Base Editing Enzymes and Applications - Deaminet 2023